Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder
Recruiting in Palo Alto (17 mi)
+11 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Naurex, Inc, an affiliate of Allergan plc
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The purpose of this study is to evaluate the efficacy and safety of NRX-1074 following a single intravenous dose in subjects with major depressive disorder.
Research Team
MD
Medical Director
Principal Investigator
Naurex, Inc, an affiliate of Allergan plc
Eligibility Criteria
Inclusion Criteria
Male and female subjects
Aged 18 to 65 years
Meets Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) criteria for major depressive disorder (MDD)
See 7 more
Treatment Details
Interventions
- NRX-1074 (NMDA receptor modulator)
Participant Groups
4Treatment groups
Experimental Treatment
Placebo Group
Group I: NRX-1074 5 mgExperimental Treatment1 Intervention
NRX-1074 5 mg, intravenous
Group II: NRX-1074 10 mgExperimental Treatment1 Intervention
NRX-1074 10 mg, intravenous
Group III: NRX-1074 1 mgExperimental Treatment1 Intervention
NRX-1074 1 mg, intravenous
Group IV: PlaceboPlacebo Group1 Intervention
Placebo
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Psychiatric Medicine AssociatesSkokie, IL
University of Kansas School of Medicine Clinical Trial UnitWichita, KS
New York State Psychiatric InstituteNew York, NY
Boston Clinical Trials, Inc.Roslindale, MA
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Naurex, Inc, an affiliate of Allergan plc
Lead Sponsor
Trials
23
Patients Recruited
6,100+
Founded
2006
Headquarters
Evanston, Illinois, USA
Known For
Depression Therapies
Top Products
Rapastinel (GLYX-13), NRX-1074